Immunome (IMNM) to Release Earnings on Monday

Immunome (NASDAQ:IMNM) is anticipated to post its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Immunome to post earnings of ($0.60) per share and revenue of $0.2220 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). On average, analysts expect Immunome to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Immunome Price Performance

Shares of NASDAQ:IMNM traded up $0.85 on Monday, reaching $23.58. 130,979 shares of the company traded hands, compared to its average volume of 1,411,672. Immunome has a fifty-two week low of $7.15 and a fifty-two week high of $27.65. The company’s 50 day moving average is $21.88 and its 200-day moving average is $20.82. The stock has a market capitalization of $2.67 billion, a PE ratio of -9.77 and a beta of 2.11.

Insider Activity at Immunome

In related news, Director Philip Wagenheim sold 28,200 shares of the business’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $20.65, for a total value of $582,330.00. Following the sale, the director directly owned 341,147 shares of the company’s stock, valued at approximately $7,044,685.55. The trade was a 7.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Jack Higgins sold 9,438 shares of the business’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $21.64, for a total transaction of $204,238.32. Following the sale, the insider directly owned 22,000 shares in the company, valued at $476,080. This trade represents a 30.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 139,438 shares of company stock valued at $2,964,664 over the last quarter. Corporate insiders own 7.21% of the company’s stock.

Institutional Investors Weigh In On Immunome

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMNM. BNP Paribas Financial Markets lifted its position in Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after buying an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after purchasing an additional 3,802 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Immunome during the 3rd quarter worth about $76,000. Velan Capital Investment Management LP acquired a new position in shares of Immunome during the 3rd quarter worth about $117,000. Finally, Quarry LP acquired a new position in shares of Immunome during the 3rd quarter worth about $117,000. 44.58% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Craig Hallum boosted their target price on shares of Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Stephens cut their target price on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $31.00 price target on shares of Immunome in a research note on Thursday, January 15th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $33.45.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.